한글목차

병원, 클리닉, 약국, 약국 시장에서의 기회로 인해 전 세계 편두통 처방약 시장 전망은 매우 유망합니다. 세계 편두통 처방약 시장은 2025-2031년 연평균 9.9%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 치료 옵션의 발전, 인식 및 진단 개선, 효능 및 환자 결과 개선입니다.

• Lucintel의 예측에 따르면, 유형별로는 스마트립탄이 시장에서 광범위하게 이용 가능하고, 제형이 다양하며, 선점 우위를 점하고 있어 예측 기간 동안 높은 성장이 예상됩니다.
• 용도별로는 드럭스토어가 접근성과 편의성, OTC와 처방전의 조합으로 높은 성장이 예상됩니다.
• 지역별로는 미국이 편두통 유병률이 전 세계에서 가장 높은 국가 중 하나이기 때문에 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.

편두통 처방약 시장의 새로운 트렌드

편두통 처방약 시장은 의학의 발전과 환자의 선호도 변화를 반영하는 몇 가지 새로운 트렌드에 의해 형성되고 있습니다. 이러한 추세는 기술 혁신을 촉진하고, 치료 결과를 개선하며, 치료 접근성을 확대하는 데 기여하고 있습니다.

• 생물학적 제제와 CGRP 억제제: CGRP 억제제의 등장은 편두통 치료의 중요한 돌파구입니다. eiming과 Agility와 같은 생물학적 제제는 편두통 과정에서 중요한 역할을 하는 칼시토닌 유전자 관련 펩타이드(CGRP) 수용체를 표적으로 삼는다. 이 계열의 약물은 기존 약물에 비해 부작용이 적은 예방적 치료를 제공하여 편두통 치료의 패러다임 전환을 가져올 수 있습니다.
• 원격의료와 디지털 헬스: 원격의료와 디지털 헬스 플랫폼의 이용이 증가하면서 편두통 치료에 변화를 가져오고 있습니다. 특히 의료 혜택이 부족한 지역에서는 전문의와의 가상 진료를 통해 환자들이 처방전 없이도 쉽게 치료를 받을 수 있게 되었습니다. 또한, 편두통 디지털 추적 도구는 환자와 의사 모두 편두통의 원인, 빈도, 중증도를 더 잘 이해하도록 도와주며, 이는 더 나은 정보에 입각한 치료 결정을 내릴 수 있도록 돕고 있습니다.
• 맞춤형 의료: 편두통 치료에 대한 개별화 접근이 증가하고 있습니다. 유전자 검사와 개인별 맞춤 치료 계획을 통해 의사는 환자 고유의 유전적 요인과 생활습관에 따라 보다 효과적인 약을 처방할 수 있습니다. 이러한 맞춤형 접근 방식은 편두통 치료 결과를 개선하고 편두통 치료제 처방의 시행착오를 줄일 수 있습니다.
• 예방치료: 편두통의 증상만을 치료하는 것이 아니라 편두통을 예방하는 것이 중요해지면서 시장이 재편되고 있습니다. CGRP 억제제나 보톡스 주사를 포함한 예방약은 환자와 의료진이 장기적으로 편두통의 빈도와 중증도를 줄이기 위해 찾는 예방약이 보편화되고 있습니다.
• 일반의약품(OTC) 통합: 일반의약품과 처방약의 통합은 새로운 트렌드입니다. 많은 환자들이 비스테로이드성 항염증제와 같은 일반의약품을 사용하여 급성 증상을 관리하고 있으며, 의사들은 보다 종합적인 접근을 위해 일반의약품과 처방약을 병용하는 경우가 많아지고 있습니다. 이러한 추세는 여러 치료 옵션을 결합한 통합 치료 모델의 필요성을 강조하고 있습니다.

이러한 추세는 보다 효과적이고 표적화된 치료법의 도입과 접근성 향상으로 편두통 치료의 전망을 바꾸고 있습니다. 생물학적 제제와 개인 맞춤형 의료가 확산되면 환자들은 보다 맞춤화되고 효과적인 치료의 혜택을 누릴 수 있고, 원격 의료와 예방적 접근은 편의성과 장기적인 치료의 편의성을 향상시킬 것입니다.

편두통 처방약 시장의 최근 트렌드

편두통 처방약 시장에는 몇 가지 주요 발전이 있었으며, 각 발전은 치료 옵션의 발전과 환자 예후 개선에 기여하고 있습니다. 이러한 개발은 의약품 기술 혁신, 환자 중심 접근 방식, 새로운 규제 당국의 승인에 의해 촉진되고 있습니다.

• CGRP 억제제 승인: aim, Agility, Agony와 같은 CGRP 억제제의 승인은 편두통 치료에 혁명을 일으켰습니다. 이들 치료제는 기존 약물에 비해 부작용이 적고 예방적 치료가 가능하기 때문에 채택이 증가하고 있습니다. 이러한 생물학적 제제는 만성 편두통 환자나 기존 치료법이 효과가 없는 환자에게 특히 유용합니다.
• 원격의료의 도입: 원격의료의 보급으로 편두통 치료가 더욱 친숙해졌고, 환자들은 직접 병원에 가지 않고도 전문의의 진료와 처방을 받을 수 있게 되었습니다. 이 개발은 전문적 치료에 대한 접근이 제한되어 있거나 의료 혜택이 충분하지 않은 지역 환자들에게 특히 중요합니다.
• 병용요법: 트립탄과 메스꺼움 방지제나 예방치료제와의 병용 등 병용요법이 보편화되고 있습니다. 이러한 다약제 병용요법은 급성 증상과 장기적인 예방에 모두 대응하는 것을 목표로 하며, 편두통 관리에 대한 보다 종합적인 접근법을 제공합니다.
• 새로운 예방약: 새로운 예방약이 시장에 출시되어 환자들에게 장기적인 관리를 위한 새로운 선택권을 제공합니다. 과거에는 주로 미용 목적으로 사용되던 보톡스가 현재는 만성 편두통 예방약으로 승인되어 의학 연구의 다른 분야에서 새로운 치료법이 탄생할 수 있는 가능성을 보여주고 있습니다.
• 규제 변화: FDA와 EMA를 비롯한 전 세계 규제 기관은 새로운 편두통 치료제를 더 빠른 속도로 승인하고 있습니다. 이번 승인으로 리펜터, 단일클론항체 등 새로운 치료제가 도입되어 환자들에게 보다 효과적이고 타겟화된 치료가 가능해졌습니다.

이러한 주요 발전으로 편두통 환자가 이용할 수 있는 치료의 폭이 넓어지고 있으며, 급성기 치료와 예방적 치료 모두 개선되고 있습니다. CGRP 억제제, 새로운 병용요법, 예방약물의 도입은 시장을 재편하고 환자에게 편두통 관리를 위한 보다 효과적이고 개별화된 선택권을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 편두통용 처방약 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• Sumatriptan : 동향과 예측(2019-2031년)
• Rizatriptan : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 세계의 편두통용 처방약 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원 : 동향과 예측(2019-2031년)
• 진료소 : 동향과 예측(2019-2031년)
• 드럭스토어 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 편두통용 처방약 시장 : 지역별

제7장 북미의 편두통용 처방약 시장

• 개요
• 북미 편두통용 처방약 시장 : 유형별
• 북미 편두통용 처방약 시장 : 용도별
• 미국 편두통용 처방약 시장
• 멕시코 편두통용 처방약 시장
• 캐나다 편두통용 처방약 시장

제8장 유럽의 편두통용 처방약 시장

• 개요
• 유럽 편두통용 처방약 시장 : 유형별
• 유럽 편두통용 처방약 시장 : 용도별
• 독일 편두통용 처방약 시장
• 프랑스 편두통용 처방약 시장
• 스페인 편두통용 처방약 시장
• 이탈리아 편두통용 처방약 시장
• 영국 편두통용 처방약 시장

제9장 아시아태평양의 편두통용 처방약 시장

• 개요
• 아시아태평양 편두통용 처방약 시장 : 유형별
• 아시아태평양 편두통용 처방약 시장 : 용도별
• 일본 편두통용 처방약 시장
• 인도 편두통용 처방약 시장
• 중국 편두통용 처방약 시장
• 한국 편두통용 처방약 시장
• 인도네시아 편두통용 처방약 시장

제10장 기타 지역(ROW)의 편두통용 처방약 시장

• 개요
• 기타 지역 편두통용 처방약 시장 : 유형별
• 기타 지역 편두통용 처방약 시장 : 용도별
• 중동 편두통용 처방약 시장
• 남미 편두통용 처방약 시장
• 아프리카 편두통용 처방약 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 편두통용 처방약 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 인수합병(M&A), 계약, 제휴 및 합작투자(JV)

제13장 밸류체인 주요 기업 개요

• 경쟁 분석
• Gsk
• Teva
• Pfizer
• Amgen
• Viatris
• Allergan
• Grunenthal

제14장 부록

• 그림 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global prescription migraine medicine market looks promising with opportunities in the hospital, clinic, and drug store markets. The global prescription migraine medicine market is expected to grow with a CAGR of 9.9% from 2025 to 2031. The major drivers for this market are advances in treatment options, increased awareness and diagnosis, and improved efficacy and patient outcomes.

• Lucintel forecasts that, within the type category, sumatriptan is expected to witness higher growth over the forecast period due to wide market availability, variety of forms, first-mover advantage.
• Within the application category, drug store is expected to witness the higher growth due to access and convenience, otc and prescription combination.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to the u.s. has one of the highest rates of migraine prevalence globally.

Emerging Trends in the Prescription Migraine Medicine Market

The prescription migraine medicine market is being shaped by several emerging trends, which reflect both advancements in medical science and shifts in patient preferences. These trends are driving innovation, improving treatment outcomes, and expanding access to care.

• Biologics and CGRP Inhibitors: The rise of CGRP inhibitors represents a significant breakthrough in migraine treatment. These biologics, such as aiming and Agility, target the calcitonin gene-related peptide (CGRP) receptor, a key player in the migraine process. This class of drugs offers preventive treatment with fewer side effects compared to traditional medications, creating a paradigm shift in how migraines are treated.
• Telemedicine and Digital Health: The increasing use of telemedicine and digital health platforms is transforming migraine care. Virtual consultations with specialists have made it easier for patients to access prescription treatments, especially in underserved areas. Moreover, digital migraine tracking tools help both patients and doctors better understand triggers, frequency, and severity, leading to more informed treatment decisions.
• Personalized Medicine: Personalized approaches to migraine treatment are on the rise. Genetic testing and individualized treatment plans allow doctors to prescribe medications that are more likely to work based on the patient's specific genetic and lifestyle factors. This tailored approach enhances treatment outcomes and reduces the trial-and-error nature of prescribing migraine medications.
• Preventive Treatments: The growing emphasis on preventing migraines, rather than just treating symptoms, is reshaping the market. Preventive medications, including CGRP inhibitors and Botox injections, are becoming more common as patients and healthcare providers seek to reduce the frequency and severity of migraines over the long term.
• Over-the-Counter (OTC) Integration: The integration of OTC solutions with prescription treatments is an emerging trend. Many patients use OTC medications like NSAIDs to manage acute symptoms, and doctors are increasingly combining these with prescription therapies for a more comprehensive approach. This trend emphasizes the need for integrated care models that combine multiple therapeutic options.

These trends are transforming the migraine treatment landscape by introducing more effective, targeted therapies and improving accessibility. As biologics and personalized medicine gain traction, patients will benefit from more tailored, effective treatments, while telemedicine and preventive approaches will increase convenience and long-term care.

Recent Developments in the Prescription Migraine Medicine Market

The prescription migraine medicine market has witnessed several key developments, each contributing to the advancement of treatment options and improving patient outcomes. These developments are driven by pharmaceutical innovation, patient-centric approaches, and new regulatory approvals.

• CGRP Inhibitors Approval: The approval of CGRP inhibitors like aiming, Agility, and Agony has revolutionized the treatment of migraine. These drugs offer preventive treatment with fewer side effects compared to traditional medications, which has led to their increased adoption. These biologics are particularly beneficial for patients with chronic migraines and those who do not respond well to conventional treatments.
• Telemedicine Adoption: The rise of telemedicine has made migraine care more accessible, allowing patients to receive consultations and prescriptions from specialists without the need for in-person visits. This development is especially significant for individuals in rural or underserved areas where access to specialized care is limited.
• Combination Therapies: Combination therapies, such as the pairing of trip tans with anti-nausea medications or preventive treatments, are becoming more common. These multi-drug strategies aim to address both acute symptoms and long-term prevention, providing a more comprehensive approach to managing migraines.
• Emerging Preventive Medications: New preventive medications are entering the market, offering patients additional options for long-term management. Botox, once used primarily for cosmetic purposes, is now approved for chronic migraine prevention, demonstrating the potential for new treatments to emerge from other areas of medical research.
• Regulatory Changes: Regulatory bodies around the world, including the FDA and EMA, have been approving new migraine treatments at a faster pace. These approvals have led to the introduction of novel therapies, such as repents and monoclonal antibodies, which offer more effective and targeted treatments for patients.

These key developments are expanding the range of treatments available to migraine sufferers, improving both acute and preventive care. The introduction of CGRP inhibitors, new combination therapies, and preventive medications is reshaping the market, providing patients with more effective and personalized options for managing migraines.

Strategic Growth Opportunities in the Prescription Migraine Medicine Market

The prescription migraine medicine market offers numerous strategic growth opportunities, particularly in areas that cater to emerging patient needs and capitalize on innovations in drug development. Key growth opportunities include expanding access to new medications, leveraging digital health technologies, and addressing unmet needs in migraine care.

• Expanding Access to CGRP Inhibitors: As CGRP inhibitors become more widely available, pharmaceutical companies have the opportunity to increase market penetration by offering these drugs at competitive prices or through insurance programs. Expanding access to these medications, particularly in emerging markets, could significantly boost sales and improve global migraine care.
• Telemedicine for Remote Consultations: The continued growth of telemedicine presents an opportunity to enhance access to prescription migraine treatments. Virtual consultations, symptom tracking apps, and online pharmacies are making it easier for patients to receive care, especially in rural and underserved areas.
• Combination Therapy Development: There is a growing opportunity in developing combination therapies that combine acute and preventive medications in a single treatment regimen. These therapies offer a more comprehensive approach to migraine management, improving patient compliance and outcomes.
• Expanding Preventive Treatment Options: With the increasing demand for preventive treatments, pharmaceutical companies can capitalize on developing and marketing new drugs aimed at preventing migraines. Expanding the range of preventive medications will address the needs of patients who experience frequent and debilitating migraines.
• Personalized Medicine Approaches: Developing personalized treatment plans based on genetic and lifestyle factors offers a significant opportunity for growth. By offering treatments that are more effective and tailored to individual patients, companies can improve treatment outcomes and patient satisfaction.

These strategic growth opportunities are reshaping the migraine medicine market, driving innovation and expanding access to effective treatments. By focusing on personalized care, expanding access to preventive options, and leveraging digital health technologies, the industry can meet the growing demand for better migraine management solutions.

Prescription Migraine Medicine Market Driver and Challenges

The prescription migraine medicine market is shaped by various drivers and challenges, which include technological advancements, regulatory factors, and the evolving needs of patients. Understanding these factors is crucial for navigating the market dynamics.

The factors responsible for driving the Prescription Migraine Medicine market include:

1. Technological Advancements: Advances in biotechnology and drug development have led to the creation of more targeted and effective migraine treatments, such as CGRP inhibitors. These innovations improve treatment outcomes and offer better options for patients with chronic migraines.

2. Increasing Awareness of Migraine: Rising awareness of migraine as a serious medical condition has led to increased demand for prescription treatments. As more people recognize the impact of migraines on quality of life, they are seeking medical solutions, driving market growth.

3. Preventive Care Demand: There is a growing demand for preventive treatments to reduce the frequency and severity of migraines. Preventive drugs, such as CGRP inhibitors and Botox, are gaining popularity, reflecting a shift toward long-term management rather than just symptomatic relief.

4. Personalized Medicine: The move toward personalized medicine is driving growth in the market. By tailoring treatments to individual patients based on their genetic profiles and lifestyle factors, healthcare providers can offer more effective migraine therapies.

5. Healthcare Access Expansion: Expanding healthcare access, especially in emerging markets, is helping to drive the growth of the prescription migraine medicine market. Increased healthcare infrastructure and the availability of health insurance are making migraine treatments more accessible.

Challenges in the Prescription Migraine Medicine market are:

1. Cost and Affordability: One of the major challenges is the high cost of newer migraine treatments, such as CGRP inhibitors, which may not be affordable for all patients. This limits access to these medications, particularly in developing markets.

2. Regulatory Hurdles: Regulatory approval processes for new drugs can be lengthy and expensive. This can delay the introduction of new treatments and limit the options available to patients.

3. Treatment Adherence: Ensuring that patients adhere to prescribed treatment regimens can be challenging, particularly when medications are expensive or have complex dosing schedules.

The prescription migraine medicine market is driven by technological advancements, increasing demand for preventive treatments, and personalized care, while challenges such as cost and regulatory hurdles need to be addressed to ensure continued growth and patient access.

List of Prescription Migraine Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prescription migraine medicine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prescription migraine medicine companies profiled in this report include-

• Gsk
• Teva
• Pfizer
• Amgen
• Viatris
• Allergan
• Grunenthal

Prescription Migraine Medicine Market by Segment

The study includes a forecast for the global prescription migraine medicine market by type, application, and region.

Prescription Migraine Medicine Market by Type [Value from 2019 to 2031]:

• Sumatriptan
• Rizatriptan
• Others

Prescription Migraine Medicine Market by Application [Value from 2019 to 2031]:

• Hospital
• Clinic
• Drug Store

Prescription Migraine Medicine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Prescription Migraine Medicine Market

The prescription migraine medicine market is undergoing rapid evolution, driven by advances in pharmacology, the rise of biologics, and a growing focus on personalized medicine. As the understanding of migraine pathophysiology improves, new treatments are emerging to provide better relief for patients. Key markets such as the United States, China, Germany, India, and Japan are seeing significant progress in the development and availability of migraine medications, expanding treatment options for patients.

• United States: The U.S. market has seen significant progress with the approval and growing adoption of CGRP inhibitors, a new class of biologics that target a protein involved in migraine attacks. Drugs like aiming, Agility, and Agony are being prescribed for preventive treatment, marking a shift from traditional trip tans. The rise of telemedicine has also improved patient access to migraine specialists, helping many patients receive timely prescriptions. Furthermore, the focus on personalized medicine is increasing, with doctors adjusting treatments based on the individual's response and genetic profile.
• China: In China, the prescription migraine medicine market is still emerging, but growing awareness of the condition is driving demand for better treatments. While trip tans remain the mainstay of treatment, the approval of newer medications, including CGRP inhibitors, is gaining traction. Chinese authorities have been working to expand access to migraine treatments, though affordability and healthcare infrastructure remain challenges. There is also increasing interest in integrating traditional Chinese medicine (TCM) with modern pharmacological treatments to address migraine symptoms, combining both approaches to cater to different patient preferences.
• Germany: Germany has a well-established migraine treatment landscape, with a strong emphasis on a combination of pharmacological and non-pharmacological therapies. The prescription market in Germany is expanding with the introduction of CGRP inhibitors and newer trip tans. There is an increasing trend toward precision medicine, with doctors prescribing treatments based on individual migraine profiles and genetic markers. Germany also benefits from a robust healthcare system, which ensures that advanced treatments, such as biologics, are accessible to a wider population.
• India: In India, the market for prescription migraine medications is growing, but many patients still rely on over-the-counter (OTC) solutions due to cost considerations. However, awareness of migraines as a serious medical condition is on the rise, which is driving demand for prescription treatments. Triptans are commonly prescribed, but newer drugs such as CGRP inhibitors are slowly entering the market, particularly in urban centers. Economic factors influence the adoption of newer treatments, with a preference for affordable options being prevalent in rural areas.
• Japan: Japan's migraine medicine market is seeing rapid advancements with a strong preference for traditional medicines alongside modern pharmacotherapies. CGRP inhibitors have been introduced, but their use is more common in specialized centers due to their high cost. Japan also has a unique approach to personalized migraine treatment, using detailed patient records to inform decisions on drug selection. Additionally, there is increasing awareness of the need for preventive treatments, which is driving the demand for newer and more effective medications.

Features of the Global Prescription Migraine Medicine Market

• Market Size Estimates: Prescription migraine medicine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Prescription migraine medicine market size by type, application, and region in terms of value ($B).
• Regional Analysis: Prescription migraine medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the prescription migraine medicine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prescription migraine medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the prescription migraine medicine market by type (sumatriptan, rizatriptan, and others), application (hospital, clinic, and drug store), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Prescription Migraine Medicine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Sumatriptan: Trends and Forecast (2019-2031)
• 4.4 Rizatriptan: Trends and Forecast (2019-2031)
• 4.5 Others: Trends and Forecast (2019-2031)

5. Global Prescription Migraine Medicine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital: Trends and Forecast (2019-2031)
• 5.4 Clinic: Trends and Forecast (2019-2031)
• 5.5 Drug Store: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Prescription Migraine Medicine Market by Region

7. North American Prescription Migraine Medicine Market

• 7.1 Overview
• 7.2 North American Prescription Migraine Medicine Market by type
• 7.3 North American Prescription Migraine Medicine Market by application
• 7.4 United States Prescription Migraine Medicine Market
• 7.5 Mexican Prescription Migraine Medicine Market
• 7.6 Canadian Prescription Migraine Medicine Market

8. European Prescription Migraine Medicine Market

• 8.1 Overview
• 8.2 European Prescription Migraine Medicine Market by type
• 8.3 European Prescription Migraine Medicine Market by application
• 8.4 German Prescription Migraine Medicine Market
• 8.5 French Prescription Migraine Medicine Market
• 8.6 Spanish Prescription Migraine Medicine Market
• 8.7 Italian Prescription Migraine Medicine Market
• 8.8 United Kingdom Prescription Migraine Medicine Market

9. APAC Prescription Migraine Medicine Market

• 9.1 Overview
• 9.2 APAC Prescription Migraine Medicine Market by type
• 9.3 APAC Prescription Migraine Medicine Market by application
• 9.4 Japanese Prescription Migraine Medicine Market
• 9.5 Indian Prescription Migraine Medicine Market
• 9.6 Chinese Prescription Migraine Medicine Market
• 9.7 South Korean Prescription Migraine Medicine Market
• 9.8 Indonesian Prescription Migraine Medicine Market

10. ROW Prescription Migraine Medicine Market

• 10.1 Overview
• 10.2 ROW Prescription Migraine Medicine Market by type
• 10.3 ROW Prescription Migraine Medicine Market by application
• 10.4 Middle Eastern Prescription Migraine Medicine Market
• 10.5 South American Prescription Migraine Medicine Market
• 10.6 African Prescription Migraine Medicine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Prescription Migraine Medicine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Gsk
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Teva
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Pfizer
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Amgen
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Viatris
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Allergan
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Grunenthal
  • Company Overview
  • Prescription Migraine Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us